12 °c
London
Sunday, December 3, 2023
No Result
View All Result
FurtherAfrica
  • Countries
    • Angola
    • Botswana
    • Cape Verde
    • DRC
    • Eswatini
    • Ethiopia
    • Kenya
    • Malawi
    • Mauritius
    • Mozambique
    • Namibia
    • Nigeria
    • Rwanda
    • South Africa
    • Tanzania
    • Uganda
    • Zambia
    • Zimbabwe
  • Interviews
  • Understanding
  • Videos
  • Travel
  • Weekend
  • About
FurtherAfrica
  • Countries
    • Angola
    • Botswana
    • Cape Verde
    • DRC
    • Eswatini
    • Ethiopia
    • Kenya
    • Malawi
    • Mauritius
    • Mozambique
    • Namibia
    • Nigeria
    • Rwanda
    • South Africa
    • Tanzania
    • Uganda
    • Zambia
    • Zimbabwe
  • Interviews
  • Understanding
  • Videos
  • Travel
  • Weekend
  • About
No Result
View All Result
FurtherAfrica
No Result
View All Result
Home Health

Moderna shot copied by WHO’s Africa may be made globally

Human trials of shot made by mRNA hub to start by May Patents may complicate development of shots for other diseases

FurtherAfrica by FurtherAfrica
September 16, 2022
in Angola, Health
Reading Time: 4 mins read
0 0
0
Africa CDC says pharma companies should cut COVID-19 vaccine prices for Africa

Afrigen Biologics & Vaccines plans to start human trials of its Covid-19 vaccine candidate by May, part of a World Health Organization-backed plan to develop locally-made inoculations in the developing world.

Afrigen, which is part of the WHO’s mRNA vaccine technology transfer hub in Cape Town, said in a joint statement the vaccine has shown “a strong immune response” in pre-clinical trials in mice. The vaccine was made by copying the publicly-available sequence of the Moderna Inc. shot provided by Stanford University.

Also read: Will Dangote’s fertilizer factory promote improving Africa’s food productivity?

The Afrigen mRNA vaccine technology transfer hub in Cape Town.

The next stage, the so-called phase 1, 2 trial, will involve about 150 people at sites near Cape Town with the aim of including both vaccinated and unvaccinated people and proving whether it can be used as an initial dose or a booster, said Petro Terblanche, Afrigen’s managing director.

The WHO set up the hub, its first, in June last year to address concerns poor countries weren’t getting sufficient access to life-saving Covid shots as the bulk of them went to affluent countries where major vaccine producers such as Moderna, Pfizer Inc. and BioNtech SE are based.

The locally-developed shots could end up being made by at least 15 production facilities in low and middle income countries around the world.

“This is the vaccine candidate that will validate the platform,” Terblanche said.

Vaccines made using messenger RNA are a breakthrough technology brought into commercial production for the first time during the pandemic. Messenger RNA can be adjusted to tackle different pathogens, potentially accelerating the development of new shots.

Also read: Meet the AfDB’s new directors including 5 women

Ultimately the WHO plans to follow the production of a Covid-19 vaccine with an attempt to develop inoculations for neglected diseases that plague the citizens of poor countries such as tuberculosis, HIV-AIDS, some forms of cancer and hemorrhagic fevers Ebola, Lassa fever and the Marburg virus.

“This is the single most exciting project in global public health,” said Charles Gore, the director of the Medicines Patent Pool, which is helping the WHO establish the hub. “It’s about empowerment,” he said at Afrigen’s laboratories in Cape Town on Monday.

Afrigen plans to transfer the technology to companies in countries including Argentina, Senegal, Bangladesh and Ukraine so that they can mass-produce it. It’s also seeking to improve the thermostability of the vaccine to allow it to be stored at normal refrigerator temperatures rather than the ultra-cold storage Moderna’s shot needs.

The first company to receive the technology will be the Biovac Institute in Cape Town, a partly government-owned company that already fills and packages vaccines for other diseases under arrangements with companies including Pfizer and Sanofi. Other companies include Biological E Ltd. in India and the Torlak institute in Serbia.

Inequity Shame

Initial attempts to get Pfizer and Moderna to assist the WHO and its hub to develop the vaccine were largely rebuffed and that’s slowed its progress, according to the WHO and Afrigen. Wide-ranging mRNA patents held by Moderna in countries including South Africa are also a threat to its future success, according to Gore.

Also read: 5 Biggest gold discoveries in Africa in 2022

Charles Gore

With “the inequity that’s been exposed here, nobody public relations wise can really afford to be seen to be doing something that continues that inequity,” Gore said.

Moderna has said it won’t enforce its patents to block the production of Covid-19 vaccines in poorer countries while the pandemic is still raging. But it’s unclear whether it would do so if the hub and other companies seek to make shots for other diseases using the mRNA platform that’s being developed.

Health and legal advocacy groups this week sent a letter to South African President Cyril Ramaphosa this week asking him to take action against Moderna’s patents .

“It is vital for the security of the mRNA hub that South Africa either revokes these patents or takes necessary executive actions to manage them,” the groups said in the letter distributed by the People’s Vaccine Alliance.

Also read: The role of banks in enabling AfCFTA

The demand for Covid-19 vaccines has slowed because more recent variants of the virus have caused milder disease. But scientists have warned that those who aren’t vaccinated are more likely to experience more severe symptoms. The virus will probably continue mutating and future variants may be more virulent.

The hub is now looking at other diseases including measles and chikungunya, a viral disease spread by mosquitoes. It also aims to develop a shot that will tackle pediatric diseases, Terblanche said.

The success of the hub and the companies it transfers technology to will depend on the willingness of governments and associations such as Gavi, the global vaccine alliance, to buy shots that initially may cost more than those made by large pharmaceutical companies.

South Africa’s Aspen Pharmacare Holdings Ltd. won a license to produce Johnson & Johnson’s Covid-19 vaccine shot and then failed to win any orders from African nations. That was because they were belatedly flooded with vaccines as demand for them waned in richer countries and they struggled to get their own citizens to take them.

Related

Source: Bloomberg
Tags: africaAfrigen Biologics & VaccinesBiological E Ltd.BioNTech SEcape townCharles GoreEbolaHealthLassa feverMarburg virusModernaModerna shot copied by WHO’s Africa may be made globallyPfizer Inc.South African President Cyril RamaphosaTorlak institutevaccine technologyWHOWorld Health Organizationафрикаأفريقياアフリカ非洲
FurtherAfrica

FurtherAfrica

Founded in 2015 FurtherAfrica is an online platform centralising news and content focusing on the development and growth story of the African continent.

Related Posts

COP 28

COP 28: Angola commits to methane reduction targets

by Fabio Scala
December 2, 2023
Mining

Angola kickstarts production at largest diamond mine

by Energy Capital & Power
December 1, 2023
Trade

Angola defends measures to speed up progress in LDCs

by FurtherAfrica
November 30, 2023
Mining

Canadian mining company invests USD6B+ in Angola diamond exploration

by FurtherAfrica
November 29, 2023
Climate

Angola calls for cooperation to mitigate the impact of climate change

by FurtherAfrica
November 24, 2023
Mozambique eVisa
 
MozParks

Translate this page

Read the Latest

COP 28

COP28: unmasking greenwashing in Africa and the challenge for sustainable development

by The Exchange
December 3, 2023
0

As COP28 unfolds with its myriad discussions and commitments, a less visible but equally critical issue looms on another continent...

Read more

COP 28: The developed world’s broken promises – How can Africa finance energy transition? – NJ Ayuk

December 3, 2023

Top night clubs in Dar es Salaam

December 3, 2023

Galp kicks off PEL 83 drilling in Namibia

December 2, 2023

ITC and TRAIDE Foundation promote direct Dutch-Ethiopian coffee trade

December 2, 2023

FurtherAfrica Partners Network

The Exchange Farmers Review Africa 360 Mozambique
TechGist Africa Energy Capital & Power Club of Mozambique
Taarifa Rwanda Web3Africa See Africa Today
Africa Global Funds Novafrica CrudeMix Africa
Harambee Africa Botswana unplugged Financial Insights Zambia
O Económico Digilogic Africa  

Subscribe to FurtherAfrica

Enter your email address to receive new articles on your email.

Join 107.2K other subscribers
FurtherAfrica

© 2021 FurtherMarkets

FurtherAfrica is a FurtherMarkets Limited platform

  • Countries
  • Interviews
  • Understanding
  • Videos
  • Travel
  • Weekend
  • About

Follow Us

No Result
View All Result
  • Countries
    • Angola
    • Botswana
    • Cape Verde
    • DRC
    • Eswatini
    • Ethiopia
    • Kenya
    • Malawi
    • Mauritius
    • Mozambique
    • Namibia
    • Nigeria
    • Rwanda
    • South Africa
    • Tanzania
    • Uganda
    • Zambia
    • Zimbabwe
  • Interviews
  • Understanding
  • Videos
  • Travel
  • Weekend
  • About

© 2021 FurtherMarkets

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?